Changes of Cell Adhesion Molecules and T Cell Subset Populations in Acute Myeloid Leukemia Patients Undergoing Intravenous Administration of Cytarabine Supplemented with Idarubicin

Table 2

The proportions of CD4⁺, CD8⁺, and CD4⁺/CD8⁺ ratio in peripheral blood in AML patients following intravenous administration of cytarabine supplemented with either idarubicin or daunorubicin.

Group	Case	Time	CD3^+ (%)	CD4^+ (%)	CD8^+ (%)	CD4^+/CD8^+
Control group	44	Pretreatment	59.15 ± 6.97	30.14 ± 3.87	34.15 ± 3.41	0.79 ± 0.08
		Posttreatment	62.74 ± 6.03	35.87 ± 3.72	32.96 ± 3.49	1.12 ± 0.12
t			8.125	6.193	0.941	3.618
			0.001	0.007	0.086	0.029
Study group	44	Pretreatment	59.17 ± 6.99	30.27 ± 3.93	34.11 ± 3.49	0.81 ± 0.09
		Posttreatment	73.80 ± 8.51^a	39.91 ± 4.76^a	29.74 ± 2.35^a	1.39 ± 0.19^a
t			12.119	7.374	5.174	4.396
			0.001	0.001	0.018	0.027

The letter a indicates compared to the control group.